Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead

Immunocore Builds on Kimmtrak Momentum

Kimmtrak generated $400 million in sales in 2025, up nearly 29% year over year. That performance reflects continued demand for the drug since its 2022 approval for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.

The product is approved in 39 countries and launched in more than 30. Higher volumes in the United States and Europe, broader reimbursement coverage and continued expansion into additional countries supported adoption.

IMCR Gains Support From Survival Data

Immunocore added an important durability point in April 2026, when five-year follow-up data from the pivotal phase III trial showed a 16% overall survival rate with Kimmtrak versus 8% for the control arm.

Median overall survival was 21.6 months with Kimmtrak compared with 16.9 months for investigator's choice. The longer record strengthens the drug's first-line positioning and may support physician confidence in eligible patients.

Immunocore Targets New Melanoma Settings

The phase III TEBE-AM study is testing Kimmtrak as monotherapy and in combination with standard-of-care checkpoint inhibitors in advanced cutaneous melanoma after prior anti-PD-(L)1 treatment.

Top-line results are expected as early as the second half of 2026. Positive data could move Kimmtrak into a larger setting where no therapy has shown an overall survival benefit after checkpoint inhibitor treatment in a randomized study.

That makes the readout important not only for Immunocore but also for the broader melanoma landscape. Bristol Myers BMY, through Opdivo, and Merck MRK, through Keytruda, remain central checkpoint-inhibitor players, giving IMCR's post-checkpoint strategy a clear competitive frame.

IMCR Pursues Earlier Uveal Melanoma Use

Immunocore is also evaluating Kimmtrak as an adjuvant therapy for uveal melanoma in the registrational phase III ATOM study, led by the European Organisation for Research and Treatment of Cancer.

Moving Kimmtrak into an earlier treatment setting could expand its reach beyond metastatic disease. The timing remains long dated, however, as enrollment in ATOM is expected to be completed in 2028.

Earlier use would also help address one of IMCR's core investment issues. Kimmtrak is the company's revenue base, so broader use within uveal melanoma could support durability even before other pipeline assets mature.

Immunocore's Stock Signals Require Context

The bottom line is that Immunocore has a real commercial foundation, but it is still a concentrated story. Kimmtrak's 2025 sales growth, first-quarter 2026 revenue growth and five-year survival data support the case for continued adoption.

The neutral view and $37 price target reflect that balance. The stock trades above the Zacks sub-industry and sector on a forward 12-month sales basis, even as its growth outlook remains tied to Kimmtrak and clinical execution.

Because a specific Zacks Rank and Style Scores are not assigned here, investors should not read this as a rank-driven call. The current signal is better framed through Kimmtrak's growth, the 2026 cutaneous melanoma catalyst, the longer ATOM timeline and the risk of relying on a single marketed product.

IMCR’s Zacks Rank

Immunocore currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research